KRAS and head and neck squamous cell carcinoma: Sotorasib is now well known for its activity in KRAS G12C mutated non-small cell lung cancers and colorectal cancer, but has yet to show efficacy in the setting of HNSCC—likely due to its overall low prevalence of 2.9% [46].